Combined Degenerative Mitral Valve and Coronary Surgery: Early Outcomes and 10-Year Survival.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
11 2020
Historique:
received: 12 07 2019
revised: 01 01 2020
accepted: 02 03 2020
pubmed: 12 4 2020
medline: 15 12 2020
entrez: 12 4 2020
Statut: ppublish

Résumé

This study investigated the impact of combined degenerative mitral valve (DMV) and coronary artery bypass grafting (CABG+DMV) surgery vs DMV surgery only on in-hospital health outcome and 10-year survival. We identified 745 patients with DMV disease. Of these, 186 (24.9%) were affected also by coronary disease and underwent combined DMV+CABG. They were compared with the remaining 559 patients receiving DMV-only surgery in in-hospital and 1-, 5-, and 10-year survival. We evaluated a short-term composite outcome of hospital mortality, acute kidney injury, cerebrovascular events, and low cardiac output requiring postoperative use of intraaortic balloon pump. In addition, we assessed mitral valve repair rates over time and their correlation with long-term survival. To minimize bias, we conducted a propensity score-matching analysis. DMV+CABG surgery was associated with a similar incidence of the composite end point compared with DMV-only surgery in the unmatched analysis (6.5% vs 5.4%, P = .71) and matched analysis (7.5% vs 8.2%, P = .82). The 10-year survival was 70.5% vs 68.6% (P = .07) for the unmatched analysis and 64.6% vs 62.5% (P = .9) for the matched analysis, DMV+CABG vs DMV-only, respectively. Mitral valve repair had a beneficial effect on short-term outcomes and long-term mortality rates, regardless the presence of concomitant coronary surgery. Combined DMV+CABG surgery is a very effective surgical treatment with high mitral valve repair rate. Early in-hospital outcome and long-term survival are comparable with DMV-only surgery. In these combined procedures, mitral valve repair is associated with better long-term survival.

Sections du résumé

BACKGROUND
This study investigated the impact of combined degenerative mitral valve (DMV) and coronary artery bypass grafting (CABG+DMV) surgery vs DMV surgery only on in-hospital health outcome and 10-year survival.
METHODS
We identified 745 patients with DMV disease. Of these, 186 (24.9%) were affected also by coronary disease and underwent combined DMV+CABG. They were compared with the remaining 559 patients receiving DMV-only surgery in in-hospital and 1-, 5-, and 10-year survival. We evaluated a short-term composite outcome of hospital mortality, acute kidney injury, cerebrovascular events, and low cardiac output requiring postoperative use of intraaortic balloon pump. In addition, we assessed mitral valve repair rates over time and their correlation with long-term survival. To minimize bias, we conducted a propensity score-matching analysis.
RESULTS
DMV+CABG surgery was associated with a similar incidence of the composite end point compared with DMV-only surgery in the unmatched analysis (6.5% vs 5.4%, P = .71) and matched analysis (7.5% vs 8.2%, P = .82). The 10-year survival was 70.5% vs 68.6% (P = .07) for the unmatched analysis and 64.6% vs 62.5% (P = .9) for the matched analysis, DMV+CABG vs DMV-only, respectively. Mitral valve repair had a beneficial effect on short-term outcomes and long-term mortality rates, regardless the presence of concomitant coronary surgery.
CONCLUSIONS
Combined DMV+CABG surgery is a very effective surgical treatment with high mitral valve repair rate. Early in-hospital outcome and long-term survival are comparable with DMV-only surgery. In these combined procedures, mitral valve repair is associated with better long-term survival.

Identifiants

pubmed: 32277884
pii: S0003-4975(20)30505-1
doi: 10.1016/j.athoracsur.2020.03.009
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1527-1533

Subventions

Organisme : British Heart Foundation
ID : PG/10/40/28369
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L012723/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L012723/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/104/32652
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/104/32652
Pays : United Kingdom
Organisme : British Heart Foundation
ID : IG/14/2/30991
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Vito D Bruno (VD)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Mustafa Zakkar (M)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Gustavo Guida (G)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Filippo Rapetto (F)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Asif Rathore (A)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Raimondo Ascione (R)

Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom. Electronic address: r.ascione@bristol.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH